Oxidative Metabolic Pathway of Lenvatinib Mediated by Aldehyde Oxidase

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

Junji Matsui, Yuji Yamamoto, Yasuhiro Funahashi et al. · International Journal of Cancer · 2007 · 547 citations

Medicine, Oncology, Pharmacology +17

Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

Junji Matsui, Yasuhiro Funahashi, Toshimitsu Uenaka et al. · Clinical Cancer Research · 2008 · 528 citations · Full text

Medicine, Oncology, Pharmacology +17

In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model

J. Brian Houston, Kathryn E. Kenworthy · Drug Metabolism and Disposition · 2000 · 392 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery

David C. Pryde, Deepak Dalvie, Qiyue Hu et al. · Journal of Medicinal Chemistry · 2010 · 346 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +10

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

Kiyoshi Okamoto, Kotaro Kodama, Kazuma Takase et al. · Cancer Letters · 2013 · 286 citations · Full text

Medicine, Oncology, Pharmacology +17